{"public_id":"cl_906d2bcc5e73ed37217c64cca8f54f3f","status":"active","superseded_by_public_id":null,"corpus_id":25407135,"text":"Bevacizumab is associated with hypertension, bleeding, and vomiting.","confidence":0.97,"paper":{"corpus_id":25407135,"title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.","url":"https://sah.borca.ai/papers/25407135"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.97,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_a2e1fa121ceae0bd5f600ef9173b8f2b","name":"bleeding","description":"Hemorrhagic adverse event reported in association with treatment.","types":["adverse event","toxicity"],"url":"https://sah.borca.ai/concepts/co_a2e1fa121ceae0bd5f600ef9173b8f2b"},{"public_id":"co_b9eb188402e3eba0e5f233cc654c2ab7","name":"hypertension","description":"Elevated blood pressure reported as a treatment-associated adverse event.","types":["adverse event","toxicity"],"url":"https://sah.borca.ai/concepts/co_b9eb188402e3eba0e5f233cc654c2ab7"},{"public_id":"co_bff3d4453c16bca060cadefac9a1070d","name":"bevacizumab","description":"A monoclonal antibody that inhibits vascular endothelial growth factor and is used as an antiangiogenic cancer therapy.","types":["drug","therapeutic agent"],"url":"https://sah.borca.ai/concepts/co_bff3d4453c16bca060cadefac9a1070d"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_906d2bcc5e73ed37217c64cca8f54f3f"}